Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma

Refractory Glaucoma Clinical Trial

Official title:
A Real-World Evidence Study to Evaluate the Safety and Effectiveness of XEN Glaucoma Treatment System (XEN) in Chinese Patients With Refractory Glaucoma

Status Completed

Clinical Trial Summary

Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma. Participants will be (prospective) or have already been (retrospective) implanted with XEN via specific urgent medical need.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04303897
Study type	Observational
Source	Allergan
Contact
Status	Completed
Phase
Start date	December 19, 2019
Completion date	March 3, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01128699` - Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma	Phase 3
Completed	`NCT05521334` - MicroPulse Transscleral Laser Cyclophotocoagulation With the Zig Zag Mode in Glaucoma.	N/A
Recruiting	`NCT00349414` - Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma	Phase 1/Phase 2
Recruiting	`NCT04921098` - CPC in Adult Refractory Glaucoma	N/A
Completed	`NCT01404364` - Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye	N/A
Completed	`NCT00971061` - Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma	Phase 3
Not yet recruiting	`NCT05230355` - Comparison Between Two Techniques of Subthreshold Diode Laser Cyclophotocoagulation in Refractory Glaucoma	N/A
Recruiting	`NCT00893490` - Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma	Phase 1